ESC 365 - Use of emgliflozin in the prevention of cardotoxicity.The EMPACARD - PILOT TRIAL. 12

Back

Delegates Premium Access

Use of emgliflozin in the prevention of cardotoxicity.The EMPACARD - PILOT TRIAL. 12 - months Follow -up

Session: Prevention of cancer therapy-related cardiovascular disease

Topic: Stratification, Prevention and Monitoring

Speaker: Doctor A. Daniele (Buenos Aires, AR)

Event: ESC Cardio-Oncology 2025

Congress Presentation

Add to my library

About the speaker

Doctor Andres Jose Daniele

Institute of Oncology Angel H. Roffo, Buenos Aires (Argentina)

1 presentation

1 follower

5 more presentations in this session

Performance of a survival staging system incorporating sST2 in patients with light chain amyloidosis

Speaker: Doctor D. Kim (Seoul, KR)

Effect of sacubitril/valsartan or enalapril on left ventricular function in patients with hematologic malignancies treated with bone marrow transplantation

Speaker: Assistant Professor D. Farmakis (Athens, GR)

Safety and efficacy of S-1-based treatment in colorectal cancer patients who switched to S-1 after development of cardiotoxicity on fluoropyrimidine-based adjuvant or neoadjuvant treatment

Speaker: Doctor S. Kinos (Tampere, FI)

Cardiomyocyte but not endothelial expression of PD-L1 is required to protect from Immune-Checkpoint-Inhibitor-Associated Myocarditis (ICIM)

Speaker: Doctor M. Heckmann (Heidelberg, DE)

Quality indicators in cardio-oncology: a survey from the working group of cardiotoxicity and cardioprotection of the italian society of cardiology (SIC)

Speaker: Associate Professor G. Novo (Palermo, IT)

Access the full session

Prevention of cancer therapy-related cardiovascular disease

Speakers: Doctor A. Daniele, Doctor D. Kim, Assistant Professor D. Farmakis, Doctor S. Kinos, Doctor M. Heckmann...

Access

About the event

ESC Cardio-Oncology 2025

20 June - 21 June 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources